NIM811 explained

NIM811 is a mitochondrial permeability transition inhibitor. Also known as N-methyl-4-isoleucine cyclosporin, it is a four-substituted cyclosporine analogue that binds to cyclophilin, however this binary complex cannot bind to calcineurin, and therefore lacks immunosuppressive activity.

NIM811 is a form of treatment for patients with the hepatitis C virus (HCV). Studies indicate a strong relationship between a treatments cyclophilin binding affinity and suppression of HCV activity.^[1] NIM811 is also being studied as a potential treatment to genetic muscular diseases such as Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) disease, diseases altering the genes for collagen VI production.^[2]

Notes and References

1. Ma. Sue. Boerner. Joanna E.. TiongYip. ChoiLai. Weidmann. Beat. Ryder. Neil S.. Cooreman. Michael P.. Lin. Kai. 2006–2009. NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon. Antimicrobial Agents and Chemotherapy. 50. 9. 2976–2982. 10.1128/AAC.00310-06. 0066-4804. 1563518. 16940091.
2. Bernardi. Paolo. Argenton. Francesco. Bonaldo. Paolo. Braghetta. Paola. Sabatelli. Patrizia. Maraldi. Nadir Mario. Merlini. Luciano. Blaauw. Bert. Tagliavini. Francesca. 2014-10-15. NIM811, a cyclophilin inhibitor without immunosuppressive activity, is beneficial in collagen VI congenital muscular dystrophy models. Human Molecular Genetics. en. 23. 20. 5353–5363. 10.1093/hmg/ddu254. 24852368. 0964-6906. free.